Boston Scientific Corporation (NYSE:BSX) : 19 Wall Street analysts covering Boston Scientific Corporation (NYSE:BSX) believe that the average level the stock could reach for the short term is $23.95. The maximum price target given is $28 and the minimum target for short term is around $20, hence the standard deviation is calculated at $2.27.
Shares of Boston Scientific Corporation rose by 1.74% in the last five trading days and 2.91% for the last 4 weeks. Boston Scientific Corporation is up 23.39% in the last 3-month period. Year-to-Date the stock performance stands at 26.74%. Also, Guggenheim Securities initiates coverage on Boston Scientific Corporation (NYSE:BSX).The analysts at the brokerage house have a current rating of Buy on the shares. The rating by the firm was issued on June 9, 2016.
Boston Scientific Corporation (NYSE:BSX) : 12 brokerage houses believe that Boston Scientific Corporation (NYSE:BSX) is a Strong Buy at current levels. 3 Analyst considers the fundamentals to be worthy of a Buy recommendation. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Boston Scientific Corporation (NYSE:BSX). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 20 Wall Street Analysts endorse the stock as a Buy with a rating of 1.63.
Boston Scientific Corporation (NYSE:BSX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $23.07 and $23.04 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $23.37. The buying momentum continued till the end and the stock did not give up its gains. It closed at $23.37, notching a gain of 1.48% for the day. The total traded volume was 11,094,745 . The stock had closed at $23.03 on the previous day.
In an insider trading activity, The Securities and Exchange Commission has divulged that Pratt Timothy A., officer (EVP, GC & Chief Admin Officer) of Boston Scientific Corp, had unloaded 24,229 shares at an average price of $22.66 in a transaction dated on June 1, 2016. The total value of the transaction was worth $549,029.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.